- Home
- CDE vs BBIO Comparison
CDE vs BBIO Comparison
Compare CDE & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDE | BBIO |
|---|---|---|
| Founded | 1928 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 15.9B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CDE | BBIO |
|---|---|---|
| Price | $21.08 | $81.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 25 |
| Target Price | $22.40 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 37.3M | 2.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 533.33 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $709,598,000.00 | $502,076,000.00 |
| Revenue This Year | $165.39 | $89.45 |
| Revenue Next Year | $12.10 | $73.78 |
| P/E Ratio | $50.26 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $12.05 | $46.81 |
| 52 Week High | $27.77 | $93.42 |
Technical Indicators
Market Signals| Indicator | CDE | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 68.49 | 51.82 |
| Support Level | $20.58 | $78.90 |
| Resistance Level | $21.47 | $85.34 |
| Average True Range (ATR) | 0.84 | 2.80 |
| MACD | 0.44 | -0.33 |
| Stochastic Oscillator | 87.65 | 35.50 |
Price Performance
Historical ComparisonAbout CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico generating maximum revenue from United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.